Position Overview:
We are seeking an experienced upstream bioprocess development professional to join Cell Culture Development (CCD) as part of Medium & Bioprocess Technologies (CCD-MBT) at the Framingham, MA site as a Principal Research Associate. CCD-MBT is globally responsible for providing solutions to process challenges through the development and application of platform cell culture media and innovative technologies throughout CCD. The candidate will be self-motivated and strongly driven to succeed while demonstrating the ability to function well within a fast-paced, dynamic and collaborative team-oriented environment. The candidate will also be inquisitive and innovative, exhibiting scientific curiosity and the ability to acquire new skills while expanding the knowledge base of the organization.
This individual will join a dynamic and motivated team charged with identifying process pain points and resolving the underlying problems, generating compelling data from relevant proof of concept studies, and designing novel process platforms in collaboration with Cell Culture Development colleagues. This is an exciting opportunity with the potential to have a significant impact on future process development and manufacturing strategies within the global Sanofi network.
Key Responsibilities:
Independently perform analysis of amino acids and vitamins by UPLC and elemental analysis by ICP-MS for at-line process monitoring samples from cell culture experiments on multiple development projects.
Suggest improvements and solutions to address new problems as they occur.
Ensure timely completion and delivery of analytical results and documentation.
Present on findings in internal scientific forums.
Interface with other development groups to facilitate knowledge transfer and troubleshoot technical problems.
Work within a broader team to evaluate and implement new technologies and ways of working to enable agility and innovation in the workflow.
Ensure the highest standards of safety and environmental compliance are maintained in the workplace.
Basic Qualifications:
Master’s degree in Chemistry, Analytical Chemistry, Biochemistry or a related discipline with a minimum of 2 years of relevant industry experience, or Bachelor’s degree with a minimum of 4 years of relevant industry experience.
Experience using and troubleshooting separation-based technologies (e.g. HPLC and UPLC assays) and mass spectrometry (preferably ICP-MS).
Experience with Bioprocess analytics and analysis of scientific datasets.
Experience with operation, maintenance, and troubleshooting of analytical laboratory equipment and instrumentation.
Solid understanding of separation sciences, in particular HPLC and UPLC.
Excellent organizational, interpersonal, communication and problem-solving skills.
Sanofi Inc. and its U.S. affiliates are Equal Opportunity and Affirmative Action employers committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status; domestic violence victim status; atypical cellular or blood trait; genetic information (including the refusal to submit to genetic testing) or any other characteristic protected by law.
#GD-SA
#LI-SA
At Sanofi diversity and inclusion is foundational to how we operate and embedded in our Core Values. We recognize to truly tap into the richness diversity brings we must lead with inclusion and have a workplace where those differences can thrive and be leveraged to empower the lives of our colleagues, patients and customers. We respect and celebrate the diversity of our people, their backgrounds and experiences and provide equal opportunity for all.
Cambridge, MA
As the specialty care global business unit of Sanofi, we are focused on rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. More than 30 years since we began, we remain just as committed to and passionate about advancing therapies that offer hope to patients and families.
Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology. In 2018, with the acquisitions of Bioverativ and Ablynx, we further expanded our focus to include rare blood disorders, bringing deep expertise in hematology.
Our ambition is to be the industry leader in specialty care. We currently provide more than 25 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.
Driven by our commitment to patients, we strive to develop strong relationships with our patient communities, listening to their perspectives so that we can truly understand their needs. These collaborations continue to guide and motivate us as we work to push the boundaries of medicine and technology to develop new and better therapies where none existed before.